跳至主要内容
临床试验/NCT04457531
NCT04457531招募中早期 1 期

A Randomized Controlled Study of LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy

China Academy of Chinese Medical Sciences1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年10月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
招募中
入组人数
60
试验地点
1
主要终点
Mean maximal nerve conduction velocity

研究概览

简要总结

Based on network pharmacology, Liuweiluobi Granule was screened to treat diabetes peripheral neuropathy with deficiency of the spleen and kidney and stasis-heat syndrome.In the preliminary animal experiment, it suggested that this granule had a significant protective effect on the peripheral motor nerves of diabetic peripheral neuropathy and the effect of anti-inflammation, and the prescription did not induce the death of zebrafish at a concentration of 1000 ug/mL, without any obvious toxicity. This study aims to evaluate the efficacy of Liuweiluobi Granule in improving neurotransmission function in patients with diabetic peripheral neuropathy through a pilot, randomized controlled study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

LiuWeiLuoBi Group

Experimental

Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.

干预措施: LiuWeiLuoBi Granule (Drug)

LiuWeiLuoBi Group

Experimental

Patients will receive the treatment of LiuWeiLuoBi Granule for 12 weeks,twice a day added to the standard medical treatment.

干预措施: Standard medical treatment (Other)

Control Group

Other

Patients will receive the standard medical treatment for 12 weeks.

干预措施: Standard medical treatment (Other)

结局指标

主要结局

Mean maximal nerve conduction velocity

时间窗: 12 weeks

Mean maximal conduction velocity of the common peroneal motor nerve (MCV) and sensory nerve (SCV)

次要结局

  • HbA1c(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • Changes in the level of aldose reductase(to 12 weeks)
  • Total lipids (TC)(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • triglycerides (TG)(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • high density lipoprotein cholesterol (HDL-C)(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • low density lipid Protein cholesterol (LDL-C).(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • Michigan Diabetic Peripheral Neuropathy Score (MDNS)(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • Toronto clinical scoring system (TCSS)(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • Quantitative symptoms scales of DPN in Traditional Chinese medicine(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • Fasting blood glucose(Baseline, 4 weeks, 8 weeks and 12 weeks)
  • 2 hrs postprandial blood glucose(Baseline, 4 weeks, 8 weeks and 12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhong Wang

Professor

China Academy of Chinese Medical Sciences

研究点 (1)

Loading locations...

相似试验

LiuWeiLuoBi Granule for the Treatment of Diabetic... | 临床试验